{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:24:55Z","timestamp":1793118295200,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.lungcan.2023.107442","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T15:26:17Z","timestamp":1702653977000},"page":"107442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"188","author":[{"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hua","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Massarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Buchschacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias R.","family":"Overbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.F.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng E.","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Schwemmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Bordogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Zeuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-5342","authenticated-orcid":false,"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2023.107442_b0005","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107442_b0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtho.2021.10.014","article-title":"Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC","volume":"17","author":"Wu","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107442_b0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107442_b0020","first-page":"OF1-OF11","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients With NTRK fusion-positive solid tumors","author":"Demetri","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107442_b0025","article-title":"Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion","volume":"2018","author":"Farago","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107442_b0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107442_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041416","article-title":"Brain metastases in lung cancers with emerging targetable fusion drivers","volume":"21","author":"Tan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2023.107442_b0040","unstructured":"US FDA, VITRAKVI Prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210861s006lbl.pdf, 2019."},{"key":"10.1016\/j.lungcan.2023.107442_b0045","unstructured":"US FDA, ROZLYTREK Prescribing information, https:\/\/www.gene.com\/download\/pdf\/rozlytrek_prescribing.pdf, 2019."},{"key":"10.1016\/j.lungcan.2023.107442_b0050","unstructured":"EU EMA, Entrectinib (ROZLYTREK) EU Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rozlytrek-epar-product-information_en.pdf, 2023."},{"key":"10.1016\/j.lungcan.2023.107442_b0055","unstructured":"EU EMA, Larotrectinib (VITRAKVI) EU Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vitrakvi-epar-product-information_en.pdf, 2019."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107442_b0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/neuonc\/noaa052","article-title":"Entrectinib, a TRK\/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein","volume":"22","author":"Fischer","year":"2020","journal-title":"Neuro Oncol."},{"issue":"13","key":"10.1016\/j.lungcan.2023.107442_b0065","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/bph.15034","article-title":"OATP1A\/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2023.107442_b0070","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO.2020.38.15_suppl.3610","article-title":"Activity and safety of larotrectinib in adult patients with TRK fusion cancer: an expanded data set","volume":"38","author":"Drilon","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107442_b0075","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/1535-7163.MCT-15-0758","article-title":"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications","volume":"15","author":"Ardini","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107442_b0080","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1021\/acs.jmedchem.6b00064","article-title":"Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor","volume":"59","author":"Menichincheri","year":"2016","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107442_b0085","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/13543784.2015.1096344","article-title":"Entrectinib: a potent new TRK, ROS1, and ALK inhibitor","volume":"24","author":"Rolfo","year":"2015","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107442_b0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2023.107442_b0095","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.2022.40.16_suppl.3099","article-title":"Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced\/metastatic NTRK fusion-positive (NTRK-fp) solid tumors","volume":"40","author":"Krzakowski","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107442_b0100","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1200\/JCO.2023.41.16_suppl.9047","article-title":"Updated efficacy and safety of entrectinib in patients (pts) with locally advanced\/ metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107442_b0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107442_b0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non\u2013small-cell lung cancer: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107442_b0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107442_b0120","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3747\/co.20.1481","article-title":"Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases","volume":"20","author":"Ali","year":"2013","journal-title":"Curr. Oncol. Toronto, Ont."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107442_b0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-017-2510-0","article-title":"Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy","volume":"134","author":"Bernhardt","year":"2017","journal-title":"J. Neurooncol"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107442_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2022.100332","article-title":"Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clinical and Research Reports"},{"key":"10.1016\/j.lungcan.2023.107442_b0135","first-page":"9024","article-title":"Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer","volume":"40","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107442_b0140","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.jtho.2022.07.150","article-title":"MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis","volume":"17","author":"Fan","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107442_b0145","doi-asserted-by":"crossref","unstructured":"S. Peters, S.M. Gadgeel, T.S.K. Mok, E. Nadal, S. Kilickap, M. Perol, J. Cadranel, S. Sugawara, C.-H. Chiu, M. Moskovitz, C.-J. Yu, T. Tanaka, R. Nersesian, S.M. Shagan, M. Maclennan, M. Mathisen, V.N.S.B. Prasad, V.R. Archer, R. Dziadziuszko, Efficacy\/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced\/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST), 40(17_suppl) (2022) LBA9023-LBA9023.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9023"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:29Z","timestamp":1759237529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":29,"alternative-id":["S0169500223009807"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107442","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107442"}}